vs
Side-by-side financial comparison of Innoviva, Inc. (INVA) and BRC Group Holdings, Inc. (RILY). Click either name above to swap in a different company.
BRC Group Holdings, Inc. is the larger business by last-quarter revenue ($188.3M vs $114.6M, roughly 1.6× Innoviva, Inc.). Innoviva, Inc. runs the higher net margin — 143.2% vs 47.9%, a 95.3% gap on every dollar of revenue. On growth, Innoviva, Inc. posted the faster year-over-year revenue change (24.8% vs -21.9%). Over the past eight quarters, Innoviva, Inc.'s revenue compounded faster (21.6% CAGR vs -15.4%).
Innoviva, Inc. is a healthcare company specializing in the development, commercialization, and royalty management of prescription therapeutics for respiratory diseases, infectious diseases, and critical care conditions. It partners with leading global pharmaceutical firms to deliver treatments for asthma, COPD and other chronic illnesses to patients across core markets including North America and Europe.
INVA vs RILY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $114.6M | $188.3M |
| Net Profit | $164.2M | $90.3M |
| Gross Margin | 66.0% | 79.5% |
| Operating Margin | 34.0% | 32.3% |
| Net Margin | 143.2% | 47.9% |
| Revenue YoY | 24.8% | -21.9% |
| Net Profit YoY | 707.4% | 1710.8% |
| EPS (diluted) | $2.19 | $2.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $114.6M | $188.3M | ||
| Q3 25 | $107.8M | $215.3M | ||
| Q2 25 | $100.3M | $188.2M | ||
| Q1 25 | $88.6M | $197.2M | ||
| Q4 24 | $91.8M | $241.0M | ||
| Q3 24 | $89.5M | $225.5M | ||
| Q2 24 | $99.9M | $256.0M | ||
| Q1 24 | $77.5M | $263.4M |
| Q4 25 | $164.2M | $90.3M | ||
| Q3 25 | $89.9M | $91.1M | ||
| Q2 25 | $63.7M | $139.5M | ||
| Q1 25 | $-46.6M | $-10.0M | ||
| Q4 24 | $20.3M | $-5.6M | ||
| Q3 24 | $1.2M | $-284.4M | ||
| Q2 24 | $-34.7M | $-433.6M | ||
| Q1 24 | $36.5M | $-49.2M |
| Q4 25 | 66.0% | 79.5% | ||
| Q3 25 | 70.1% | 83.7% | ||
| Q2 25 | 82.9% | 81.3% | ||
| Q1 25 | 82.7% | 81.4% | ||
| Q4 24 | 85.1% | 79.8% | ||
| Q3 24 | 81.6% | 82.1% | ||
| Q2 24 | 85.1% | 84.5% | ||
| Q1 24 | 77.5% | 85.3% |
| Q4 25 | 34.0% | 32.3% | ||
| Q3 25 | 32.1% | 30.4% | ||
| Q2 25 | 48.6% | 5.7% | ||
| Q1 25 | 46.7% | -31.2% | ||
| Q4 24 | 47.0% | -69.2% | ||
| Q3 24 | 48.3% | -36.4% | ||
| Q2 24 | 54.7% | -90.8% | ||
| Q1 24 | 33.3% | -6.1% |
| Q4 25 | 143.2% | 47.9% | ||
| Q3 25 | 83.4% | 42.3% | ||
| Q2 25 | 63.5% | 74.1% | ||
| Q1 25 | -52.6% | -5.1% | ||
| Q4 24 | 22.1% | -2.3% | ||
| Q3 24 | 1.4% | -126.1% | ||
| Q2 24 | -34.7% | -169.4% | ||
| Q1 24 | 47.1% | -18.7% |
| Q4 25 | $2.19 | $2.78 | ||
| Q3 25 | $1.08 | $2.91 | ||
| Q2 25 | $0.77 | $4.50 | ||
| Q1 25 | $-0.74 | $-0.39 | ||
| Q4 24 | $0.43 | $-0.01 | ||
| Q3 24 | $0.02 | $-9.39 | ||
| Q2 24 | $-0.55 | $-14.35 | ||
| Q1 24 | $0.46 | $-1.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $550.9M | $226.6M |
| Total DebtLower is stronger | — | $1.4B |
| Stockholders' EquityBook value | $1.2B | $-171.5M |
| Total Assets | $1.6B | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $550.9M | $226.6M | ||
| Q3 25 | $476.5M | $184.2M | ||
| Q2 25 | $397.5M | $267.4M | ||
| Q1 25 | $319.1M | $138.3M | ||
| Q4 24 | $305.0M | $146.9M | ||
| Q3 24 | $260.6M | $159.2M | ||
| Q2 24 | $217.0M | $236.9M | ||
| Q1 24 | $178.4M | $190.7M |
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | $-171.5M | ||
| Q3 25 | $1.0B | $-260.5M | ||
| Q2 25 | $714.8M | $-351.7M | ||
| Q1 25 | $646.9M | $-496.8M | ||
| Q4 24 | $691.2M | $-488.2M | ||
| Q3 24 | $668.5M | $-497.6M | ||
| Q2 24 | $665.5M | $-218.3M | ||
| Q1 24 | $703.7M | $228.4M |
| Q4 25 | $1.6B | $1.7B | ||
| Q3 25 | $1.4B | $1.7B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.3B | $1.5B | ||
| Q4 24 | $1.3B | $1.8B | ||
| Q3 24 | $1.2B | $2.2B | ||
| Q2 24 | $1.2B | $3.2B | ||
| Q1 24 | $1.3B | $5.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $54.5M | $26.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 0.33× | 0.29× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $54.5M | $26.2M | ||
| Q3 25 | $49.7M | $-60.6M | ||
| Q2 25 | $44.1M | $-25.6M | ||
| Q1 25 | $48.6M | $184.0K | ||
| Q4 24 | $59.2M | $-2.7M | ||
| Q3 24 | $48.7M | $19.5M | ||
| Q2 24 | $43.7M | $111.5M | ||
| Q1 24 | $37.0M | $135.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $48.4M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 54.1% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | 0.33× | 0.29× | ||
| Q3 25 | 0.55× | -0.66× | ||
| Q2 25 | 0.69× | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.91× | — | ||
| Q3 24 | 40.14× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.01× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
INVA
| Royalty | $54.9M | 48% |
| Xacduro | $32.1M | 28% |
| Giapreza | $19.6M | 17% |
| Xerava | $7.3M | 6% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
